Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Melissa E. Hogg"'
Autor:
Amer H. Zureikat, Patrick R. Varley, Johanna E. Bellon, Connor Buchholz, Melissa E. Hogg, Aatur D. Singhi, Amr I. Al Abbas, Nathan Bahary, Jacob C. Hodges, Herbert J. Zeh
Publikováno v:
Journal of Clinical Oncology. 37:e15724-e15724
e15724 Background: Surgery followed by adjuvant chemotherapy (SF) is the standard approach for localized pancreatic adenocarcinoma (PC). Although neoadjuvant chemotherapy (NC) is being increasingly used, its efficacy remains debatable. This study aim
Autor:
Nathan Bahary, Herbert J. Zeh, Mashaal Dhir, Amer H. Zureikat, Aatur D. Singhi, Mazen S. Zenati, Melissa E. Hogg, Ahmad Hamad
Publikováno v:
Journal of Clinical Oncology. 36:402-402
402 Background: Comparative effectiveness of FOLFIRINOX and Gemcitabine/nab-paclitaxel (G-nP) in the neoadjuvant treatment (NAT) of pancreatic ductal adenocarcinoma (PDA), remains unknown. The aim of this study was to perform a propensity matched ana
Autor:
Amer H. Zureikat, Melissa E. Hogg, Jennifer Steve, Filip Bednar, Sharon Winters, Lee M. Ocuin, Mazen S. Zenati, Nathan Bahary, Herbert J. Zeh
Publikováno v:
Journal of Clinical Oncology. 34:399-399
399 Background: Locally advanced (LA) unresectable pancreatic adenocarcinoma (PDA) historically portends a poor prognosis with a median OS of 9-11 months. Recently, two multi-drug regimens – FOLFIRINOX and gemcitabine/nab-paclitaxel – have proven
Autor:
David L. Bartlett, Amer H. Zureikat, Mazen S. Zenati, Melissa E. Hogg, Jennifer Miller, Jennifer Steve, Herbert J. Zeh, Nathan Bahary, Lee M. Ocuin, Aatur D. Singhi, Steven A. Burton
Publikováno v:
Journal of Clinical Oncology. 34:311-311
311 Background: The role of RT following PD for PDA remains controversial due to ambiguity in the definition of R0/R1 margin status in existing clinical trials. Recent data suggest that increased margin clearance (MC) is associated with improved surv